2021
Detailed Phenotype of GLA Variants Identified by the Nationwide Neurological Screening of Stroke Patients in the Czech Republic
REKOVA, Petra, Gabriela DOSTALOVA, David KEMLINK, Jaroslava SCHWABOVA PAULASOVA, Zora DUBSKA et. al.Základní údaje
Originální název
Detailed Phenotype of GLA Variants Identified by the Nationwide Neurological Screening of Stroke Patients in the Czech Republic
Autoři
REKOVA, Petra (203 Česká republika), Gabriela DOSTALOVA (203 Česká republika), David KEMLINK (203 Česká republika, garant), Jaroslava SCHWABOVA PAULASOVA (203 Česká republika), Zora DUBSKA (203 Česká republika), Manuela VANECKOVA (203 Česká republika), Martin MASEK (203 Česká republika), Ondrej KODET (203 Česká republika), Helena POUPETOVA (203 Česká republika), Stella MAZUROVA (203 Česká republika), Aneta RAJDOVÁ (203 Česká republika, domácí), Eva VLČKOVÁ (203 Česká republika, domácí), Alena TABORIKOVA (203 Česká republika), Stepanka FAFEJTOVA (203 Česká republika), Miroslava NEVSIMALOVA (203 Česká republika), Ales LINHART (203 Česká republika) a Ales TOMEK (203 Česká republika)
Vydání
Journal of Clinical Medicine, Basel, MDPI, 2021, 2077-0383
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30218 General and internal medicine
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 4.964
Kód RIV
RIV/00216224:14110/21:00123211
Organizační jednotka
Lékařská fakulta
UT WoS
000690449900001
Klíčová slova anglicky
Fabry disease; GLA gene variants; phenotype; stroke; screening programs; data sharing
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 10. 12. 2021 14:39, Mgr. Tereza Miškechová
Anotace
V originále
Fabry disease (FD) is a rare X-linked disorder of glycosphingolipid metabolism caused by pathogenic variants within the alpha-galactosidase A (GLA) gene, often leading to neurological manifestations including stroke. Multiple screening programs seeking GLA variants among stroke survivors lacked detailed phenotype description, making the interpretation of the detected variant's pathogenicity difficult. Here, we describe detailed clinical characteristics of GLA variant carriers identified by a nationwide stroke screening program in the Czech Republic. A total of 23 individuals with 8 different GLA variants were included in the study. A comprehensive diagnostic workup was performed by a team of FD specialists. The investigation led to the suggestion of phenotype reclassification for the G325S mutation from late-onset to classical. A novel variant R30K was found and was classified as a variant of unknown significance (VUS). The typical manifestation in our FD patients was a stroke occurring in the posterior circulation with an accompanying pathological finding in the cerebrospinal fluid. Moreover, we confirmed that cornea verticillata is typically associated with classical variants. Our findings underline the importance of detailed phenotype description and data sharing in the correct identification of pathogenicity of gene variants detected by high-risk-population screening programs.